<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41919">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01967524</url>
  </required_header>
  <id_info>
    <org_study_id>RC13_0061</org_study_id>
    <nct_id>NCT01967524</nct_id>
  </id_info>
  <brief_title>Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain</brief_title>
  <acronym>MYOTOX</acronym>
  <official_title>Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myofascial pains are frequently found during the clinical examination of the patients
      presenting a painful chronic syndrome of the pelvis or the perineum. If the physiopathology
      of this component of the pain characterized by triggerpoints found in the clinical
      examination, remains uncertain; its coverage contributes to the improvement of the global
      pain of the patient. The physiotherapy can be useful but when it is not useful, we proposed
      injections of triggerpoints by local anesthetics. The injections of botulinum toxin on these
      triggerpoints have a legitimacy (action on the muscular cramp and action on the afferent
      fibers) but are they superior to the injections of local anesthetics of triggerpoints? The
      literature remains poor on the subject, justifying this randomized double-blind protocol
      comparing the efficacy of the botulinum toxin associated with a local anesthetic versus
      local anesthetic alone with a main criterion of evaluation in 2 months and a monthly
      follow-up as long as the patient remains improved and maximum in 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evolution of the PGI-I (Patient Global Impression of Improvement)</measure>
    <time_frame>2 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>The main objective is to evaluate the efficacy of injection of botulinum toxin A associated with ropivacaïne versus ropivacaïne alone on the global suffering of chronic myofascial pelviperineal syndromes two month after the injection.
The success will be defined as an improvement of the PGI-I corresponding to the first 2 levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pain on digital scale (EN)</measure>
    <time_frame>6 month</time_frame>
    <description>Evaluation of pain on digital scale (EN), each month after the injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the changing parameters of quality of life: global improvement score / treatment satisfaction assessed by digital scale, international pain scales (MPI, QDSA, QCD) / Beck and HAD score</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the evolution of analgesics consumption (score MQS)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myofascial Pelviperineal Pain</condition>
  <arm_group>
    <arm_group_label>botulinum toxin A + ropivacaïne</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaïne</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin A + ropivacaïne</intervention_name>
    <description>D0 :
Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)
QDSA (Saint-Antoine pain questionnaire)
QCD (Pain questionnaire)
MPI (Multidimensional Pain Inventory)
Beck scale
HAD (Hospital Anxiety and Depression scale)
SF36 (Short Form 36)
injection of botulinum toxin A associated with ropivacaïne
D30, D90, D120 and D150 (phone call): Calcul of the average of EN
D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).</description>
    <arm_group_label>botulinum toxin A + ropivacaïne</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaïne</intervention_name>
    <description>D0 :
Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)
QDSA (Saint-Antoine pain questionnaire)
QCD (Pain Questionnaire)
MPI (Multidimensional Pain Inventory)
Beck scale
HAD (Hospital Anxiety and Depression scale)
SF36 (Short Form 36)
injection of ropivacaïne alone
D30, D90, D120 and D150 (phone call): Calcul of the average of EN
D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).</description>
    <arm_group_label>Ropivacaïne</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Patient presenting a &quot;dysfunctional&quot; pain of the pelvis or the perineum (without
             lesional pathology justifying a specific treatment) by an endopelvic touch

          -  Pain evolving since at least 6 months and persisting in spite of the analgesic
             treatments and the physiotherapy

          -  Patient presenting to the clinical examination one or several active triggerpoints
             found on the internal obturating muscles and/or elevators of the anus, with a maximum
             of 10 triggerpoints on the whole body.

          -  Patient presenting an average of the maximal pains of the week before the inclusion
             superior or equal to 4 and inferior or equal to 9/10 (evaluation of the daily maximal
             pain on a digital scale from 0 to 10)

          -  Signed informed consent

          -  Subjects affiliated with an appropriate social security system

        Exclusion Criteria:

          -  Patients with bleeding risk and anticoagulant therapy

          -  Intolerance of botulinum toxin A, ropivacaïne and nitrous oxide

          -  Injection of botulinum toxin in any place whatsoever in the previous 3 months

          -  Pregnancy and breast feeding

          -  Antibiotic treatment by aminoglycosides

          -  Recent anti-inflammatory treatment

          -  Severe myasthenia

          -  Lambert-Eaton syndrome

          -  Patients with neurological disorders, dysphagia, food choking or inhalation pneumonia

          -  Beck score &gt; 16

          -  Patients having an average of the maximal pains of the previous week lower than 4
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques LABAT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Jacques LABAT, Dr</last_name>
    <phone>02 40 08 39 12</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Axium</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13097</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric BAUTRANT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Eric BAUTRANT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Besançon University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice MICHEL, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice MICHEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit RABISCHONG, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Benoit RABISCHONG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques , LABAT</last_name>
      <phone>02 40 08 39 12</phone>
    </contact>
    <investigator>
      <last_name>Jean-Jacques LABAT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibault RIANT, Dr</last_name>
      <phone>02 28 27 23 15</phone>
    </contact>
    <investigator>
      <last_name>Thibault RIANT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte FATTON, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Brigitte FATTON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne LASSAUX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Anne LASSAUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent SIPROUDHIS, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Laurent SIPROUDHIS, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Réunion University Hospital</name>
      <address>
        <city>Saint Denis de la Réunion</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie EGGERMONT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Julie EGGERMONT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 18, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myofascial pain</keyword>
  <keyword>Perineal pain</keyword>
  <keyword>Chronic pelvic pain</keyword>
  <keyword>Botulinum toxin type A</keyword>
  <keyword>Ropivacaïne</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
